Terminated PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT00042406

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker

A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Clinical Trial of Anti-CD4 Receptor Human Monoclonal Antibody (HuMax-CD4) in Patients With Active Rheumatoid Arthritis Failing Treatment With Methotrexate and TNF-alpha Blocking Agents

Sponsor: Genmab

Conditions Rheumatoid Arthritis

Interventions HuMax-CD4 Humax-CD4 Placebo

Updated 8 times since 2017 Last updated: Apr 26, 2023 Started: Mar 4, 2002 Primary completion: Mar 31, 2003 Completion: Mar 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Genmab

See all terminations from Genmab

Other Rheumatoid Arthritis trials with similar outcome

Browse all Rheumatoid Arthritis trials

A PHASE2/PHASE3 clinical study on Rheumatoid Arthritis, this trial is terminated or withdrawn. The trial is conducted by Genmab and has accumulated 8 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2023 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Jan 2021 — May 2023 [monthly]

Terminated PHASE2_PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2_PHASE3

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genmab

Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bend, United States , Bethlehem, United States , Boston, United States , Canfield, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , Decatur, United States , Delray Beach, United States , Des Moines, United States and 42 more locations